213 related articles for article (PubMed ID: 36179686)
1. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.
Chan KL; Gomez J; Cardinez C; Kumari N; Sparbier CE; Lam EYN; Yeung MM; Garciaz S; Kuzich JA; Ong DM; Brown FC; Chan YC; Vassiliadis D; Wainwright EN; Motazedian A; Gillespie A; Fennell KA; Lai J; House IG; Macpherson L; Ang CS; Dawson SJ; Beavis PA; Wei AH; Burr ML; Dawson MA
Cancer Cell; 2022 Oct; 40(10):1190-1206.e9. PubMed ID: 36179686
[TBL] [Abstract][Full Text] [Related]
2. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
[TBL] [Abstract][Full Text] [Related]
3. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
4. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
5. Regulation of MHC class II expression in human T-cell malignancies.
Holling TM; Schooten E; Langerak AW; van den Elsen PJ
Blood; 2004 Feb; 103(4):1438-44. PubMed ID: 14563641
[TBL] [Abstract][Full Text] [Related]
6. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
7. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.
Rimando JC; Chendamarai E; Rettig MP; Jayasinghe R; Christopher MJ; Ritchey JK; Christ S; Kim MY; Bonvini E; DiPersio JF
Blood; 2023 Apr; 141(14):1718-1723. PubMed ID: 36563336
[TBL] [Abstract][Full Text] [Related]
8. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.
Toffalori C; Zito L; Gambacorta V; Riba M; Oliveira G; Bucci G; Barcella M; Spinelli O; Greco R; Crucitti L; Cieri N; Noviello M; Manfredi F; Montaldo E; Ostuni R; Naldini MM; Gentner B; Waterhouse M; Zeiser R; Finke J; Hanoun M; Beelen DW; Gojo I; Luznik L; Onozawa M; Teshima T; Devillier R; Blaise D; Halkes CJM; Griffioen M; Carrabba MG; Bernardi M; Peccatori J; Barlassina C; Stupka E; Lazarevic D; Tonon G; Rambaldi A; Cittaro D; Bonini C; Fleischhauer K; Ciceri F; Vago L
Nat Med; 2019 Apr; 25(4):603-611. PubMed ID: 30911134
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
10. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome.
Schieber M; Marinaccio C; Bolanos LC; Haffey WD; Greis KD; Starczynowski DT; Crispino JD
Blood Cancer J; 2020 Oct; 10(10):98. PubMed ID: 33024076
[TBL] [Abstract][Full Text] [Related]
11. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
Christopher MJ; Petti AA; Rettig MP; Miller CA; Chendamarai E; Duncavage EJ; Klco JM; Helton NM; O'Laughlin M; Fronick CC; Fulton RS; Wilson RK; Wartman LD; Welch JS; Heath SE; Baty JD; Payton JE; Graubert TA; Link DC; Walter MJ; Westervelt P; Ley TJ; DiPersio JF
N Engl J Med; 2018 Dec; 379(24):2330-2341. PubMed ID: 30380364
[TBL] [Abstract][Full Text] [Related]
12. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
[TBL] [Abstract][Full Text] [Related]
13. Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse.
Gambacorta V; Beretta S; Ciccimarra M; Zito L; Giannetti K; Andrisani A; Gnani D; Zanotti L; Oliveira G; Carrabba MG; Cittaro D; Merelli I; Ciceri F; Di Micco R; Vago L
Cancer Discov; 2022 Jun; 12(6):1449-1461. PubMed ID: 35255120
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
15. Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression.
Bhat KP; Truax AD; Brooks JK; Greer SF
Immunol Cell Biol; 2010; 88(8):807-16. PubMed ID: 20351748
[TBL] [Abstract][Full Text] [Related]
16. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho JNHG; Schmidt D; Lowinus T; Ryoo J; Dopfer EP; Gonzalo Núñez N; Costa-Pereira S; Toffalori C; Punta M; Fetsch V; Wertheimer T; Rittmann MC; Braun LM; Follo M; Briere C; Vinnakota JM; Langenbach M; Koppers F; Shoumariyeh K; Engel H; Rückert T; Märklin M; Holzmayer S; Illert AL; Magon F; Andrieux G; Duquesne S; Pfeifer D; Staniek J; Rizzi M; Miething C; Köhler N; Duyster J; Menssen HD; Boerries M; Buescher JM; Cabezas-Wallscheid N; Blazar BR; Apostolova P; Vago L; Pearce EL; Becher B; Zeiser R
Blood; 2022 Sep; 140(10):1167-1181. PubMed ID: 35853161
[TBL] [Abstract][Full Text] [Related]
17. A membrane-associated MHC-I inhibitory axis for cancer immune evasion.
Chen X; Lu Q; Zhou H; Liu J; Nadorp B; Lasry A; Sun Z; Lai B; Rona G; Zhang J; Cammer M; Wang K; Al-Santli W; Ciantra Z; Guo Q; You J; Sengupta D; Boukhris A; Zhang H; Liu C; Cresswell P; Dahia PLM; Pagano M; Aifantis I; Wang J
Cell; 2023 Aug; 186(18):3903-3920.e21. PubMed ID: 37557169
[TBL] [Abstract][Full Text] [Related]
18. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
Mutis T; Schrama E; Melief CJ; Goulmy E
Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
[TBL] [Abstract][Full Text] [Related]
19. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
20. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines.
Tschickardt ME; Lu Y; Jacim M; Ussery GD; Steimle V; Mach B; Blanck G
Int J Cancer; 1995 Aug; 62(4):461-5. PubMed ID: 7635572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
